Submitted:
04 July 2025
Posted:
08 July 2025
You are already at the latest version
Abstract
Keywords:
1. Introduction
2. Methodology
2.1. Study Design and Setting
2.2. Data Collection
2.3. ASP Interventions
2.3.1. Implementation of a Data-Driven Feedback System Specifically on Antibiotic Use in Surgical Prophylaxis
2.3.2. Targeted Education Sessions for Cardiologists
2.3.3. Stakeholder Engagement by Identifying ASP Champions in Department of Cardiology and Partnering them in ASP Activities
2.3.4. Clinical Pathway Optimization Through Revisions to the Coordinated Clinical Pathway (CCP) for Pacemaker Insertion and Generator Change.
2.4. Statistical Methods
3. Results
3.1. Surgical Prophylaxis
3.2. Surgical Site Infection Rates
3.3. Proportion of Inpatients on Antibiotics


4. Discussion
4.1. Impact of ASP on Extended Surgical Prophylaxis
4.2. Impact of Standard vs Extended Prophylaxis on Surgical Site Infections, Clinical Care and Healthcare Costs
4.3. Impact of ASP Interventions on Surgical Prophylaxis with Spillover Effects on Antibiotic Consumption
4.4. Study Limitations
5. Conclusion

Author Contributions
Funding
Institutional Review Board Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
References
- Barlam TF, Cosgrove SE, Abbo LM et a. SHEA/IDSA Clinical Practice Guidelines for Implementing an Antimicrobial Stewardship Program. Clinical Infectious Diseases 2016, 62, e51–e77.
- Loo LW, Liew YX, Lee W et al. Discontinuation of antibiotic therapy within 24 hours of treatment initiation for patients with no clinical evidence of bacterial infection: a 5-year safety and outcome study from Singapore General Hospital Antimicrobial Stewardship Program. International Journal of Antimicrobial Agents 2019, 53, 606–611.
- Liew YX, Lee W, Loh JCZ et al. Impact of an antimicrobial stewardship programme on patient safety in Singapore General Hospital. International Journal of Antimicrobial Agents 2012, 40, 55–60.
- Ng TM, Ang LW, Heng ST et al. Antibiotic utilisation and resistance over the first decade of nationally funded antimicrobial stewardship programmes in Singapore acute-care hospitals. Antimicrobial Resistance & Infection Control 2023, 12, 82.
- Cai YY, Venkatachalam I, Tee NW et al. Prevalence of Healthcare-Associated Infections and Antimicrobial Use Among Adult Inpatients in Singapore Acute-Care Hospitals: Results From the First National Point Prevalence Study. Clinical Infectious Diseases 2017, 64, S61–7.
- Versporten A, Zarb P, Caniaux I et al. Antimicrobial consumption and resistance in adult hospital inpatients in 53 countries: results of an internet-based global point prevalence study. Lancet Glob Health 2018, 6, e619–29.
- Kusumoto FM, Schoenfeld MH, Wilkoff BL, et al. 2017 HRS expert consensus statement on cardiovascular implantable electronic device lead management and extraction [published correction appears in Heart Rhythm October 2021;18:1814]. Heart Rhythm. 2017;14:e503-e551. [CrossRef]
- Baddour LM, Epstein AE, Erickson CC, et al. Update on cardiovascular implantable electronic device infections and their management: a scientific statement from the American Heart Association. Circulation. 2010;121:458-477. [CrossRef]
- Khan JN, Subramaniam V, Hee C et al. Antibiotic prophylaxis for permanent pacemaker implantation: an observational study of practice in England. Br J Cardiol 2010;17:144-7.
- Oliveira JCD, Martinelli M, Nishioka SAD et al. Efficacy of antibiotic prophylaxis before the implantation of pacemakers and cardioverter-defibrillators: results of a large, prospective, randomized, double-blinded, placebo-controlled trial. Circulation: Arrhythmia Electrophysiology. 2009, 2, 29–34.
- Da Costa A, Kirkorian G, Cucherat M et al. Antibiotic prophylaxis for permanent pacemaker insertion: a meta-analysis. Circulation 1998, 97, 1796–801. [Google Scholar] [CrossRef]
- Lee W, Huang T, Lin L et al. Efficacy of postoperative prophylactic antibiotics in reducing permanent pacemaker infections. Clinical Cardiology 2017, 40, 559–565.
- Kabulski GM, Northup A, Wiggins BS. Postoperative Antibiotic Prophylaxis Following Cardiac Implantable Electronic Device Placement. J Innov Cardiac Rhythm Manage 2019, 10, 3777–3784.
- Krahn AD, Longtin Y, Philippon F et al. Prevention of Arrhythmia Device Infection Trial – The PADIT Trial. Journal of the American College of Cardiology 2018, 72, 3098–3109.
- Rennert-May E, Leal J, Zhang Z et al. Rates of post procedural prophylactic antibiotic use following cardiac implantable electronic device insertion and the impact on surgical site infections in Alberta, Canada. Antimicrobial Resistance and Infection Control 2024, 13, 147.
- Centers for Disease Control and Prevention (CDC). National Healthcare Safety Network (NHSN) Patient Safety Component Manual. Chapter 9: Surgical Site Infection (SSI) Event. Atlanda, GA: CDC 2024.
- Surat G, Bernsen D, Schimmer C. Antimicrobial Stewardship measures in cardiac surgery and its impact on surgical site infections. J Cardiothorac Surg 2021, 16, 309.
- Charani E, Edwards R, Sevdalis N et al. Behavior Change Strategies to Influence Antimicrobial Prescribing in Acute Care: A Systematic Review. Clinical Infectious Diseases 2011, 53, 651–662.
- Davey P, Peden C, Charani E et al. Time for action – improving the design and reporting of behaviour change interventions for antimicrobial stewardship in hospitals: early findings from a systematic review. International Journal of Antimicrobial Agents 2015, 45, 203–212.
- Davey P, Marwick CA, Scott CL et al. Interventions to improve antibiotic prescribing practices for hospital inpatients (Review). Cochrane Database of Systematic Reviews 2017, Issue 2. Art. No.: CD003543.
- Zheng K, Xie Y, Dan L et al. Effectiveness of Educational Interventions for Health Workers on Antibiotic Prescribing in Outpatient settings in China: A Systematic Review and Meta-Analysis. Antibiotics 2022, 11, 791.
- Yong CW, Choe R, Chua SKX et al. Utilising a COM-B framework to modify antibiotic prescription behaviours following third molar surgeries. 2025.
- Cialdini RB 2009. Influence: The psychology of persuasion (revised edition).
- Borek AJ, Campbell A, Dent E et al. Development of an intervention to support the implementation of evidence-based strategies for optimising antibiotic prescribing in general practice. Implementation Science Communication 2021 (2): 104.
- Hurst AL, Child J, Pearce K et al. Handshake Stewardship: A Highly Effective Rounding-based Antimicrobial Optimization Service. Pediatric Infectious Disease Journal 2016, 35, 1104–10.
- Neuner EA, Atkinson A, Ilges D et al. Mixed methods evaluation of handshake antimicrobial stewardship on adult inpatient medicine floors. Antimicrob Steward Healthc Epidemiol 2023, 3, e210.
- Kosharek A, Neuner E, Welch E et al. Handshake Antimicrobial stewardship for adult surgical patients. Antimicrob Steward Healthc Epidemiol 2025, 5, 46.
- Martinez-Sobalvarro JV, Junior AAP, Pereira LB et al. Antimicrobial stewardship for surgical antibiotic prophylaxis and surgical site infections: a systematic review. Int J Clin Pharm 2022, 44, 301–319.
- Asundi A, Stanislawski M, Mehta P et al. Prolonged antimicrobial prophylaxis following cardiac device procedures increases preventable harm: insights from the VA CART program. Infect Control Hosp Epidemiol 2018, 39, 1030–1036.
- Baillargeon J, Holmes HM, Lin Y et al. Concurrent Use of Warfarin and Antibiotics and the Risk of Bleeding in Older Adults. Am J Med 2012, 125, 183–189.
- Spanakis M, Alon-Ellenbogen D, Ioannou P et al. Antibiotics and Lipid-Modifying Agents: Potential Drug-Drug Interactions and Their Clinical Implications. Pharmacy 2023; 11 (4): 130.
- Vega AJ, Smith C, Matejowsky HG et al. Warfarin and Antibiotics: Drug Interactions and Clinical Considerations. Life 2023, 13, 1661.
| Standard Prophylaxis N = 380 |
Extended Prophylaxis N = 399 |
p-value | |
|---|---|---|---|
| Male (%) | 241 (63.4) | 244 (61.2) | 0.514 |
| Patients with diabetes mellitus (%) | 131 (34.5) | 147 (36.8) | 0.446 |
| Mean weight (kg) ± S.D. | 62.7 ± 15.9 | 62.4 ± 14.2 | 0.295 |
| Mean age ± S.D. | 72.5 ± 12.3 | 73.0 ± 13.9 | 0.728 |
| No. of MRSA colonisation (%) | 6 (1.6) | 9 (2.3) | 0.492 |
| Antibiotics used in prophylaxis IV Cefazolin (%) IV Vancomycin (%) PO Cefalexin (%) PO Cefuroxime (%) PO Clindamycin (%) |
304 (80.0) 76 (20.0) N.A. N.A. N.A. |
N.A. N.A. 8 (2.0) 368 (92.2) 23 (5.8) |
|
| Mean duration of oral antibiotics used in extended prophylaxis ± S.D. (days) | N.A. | 3.3 ± 0.8 | |
| No. of surgical site infections (%) | 3 (0.8) | 3 (0.8) |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2025 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).